First-line treatment of camrelizumab combined with chemotherapy in advanced gastroenteropancreatic neuroendocrine carcinoma: study protocol for a prospective, multicenter, phase ii study

HIGHLIGHTS

• who: Xiaofen Li from the University of Brescia, Italy have published the paper: First-line treatment of camrelizumab combined with chemotherapy in advanced gastroenteropancreatic neuroendocrine carcinoma: Study protocol for a prospective, multicenter, phase II study, in the Journal: (JOURNAL) of 21/01/2022
• how: Inspired by preclinical work and immunotherapy in small cell lung cancer the authors conducted this study to explore the benefit of an anti-PD-1 antibody camrelizumab combined with chemotherapy as first-line treatment in advanced GEPNEC patients.
• future: Prospective studies with new treatment approaches are in urgent need . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.